IL120997A - Pharmaceutical preparations containing a history of xanthine are converted into positions 1 and 3 for the treatment and prevention of shock conditions, a number of such new compounds, and a process for their preparation. - Google Patents

Pharmaceutical preparations containing a history of xanthine are converted into positions 1 and 3 for the treatment and prevention of shock conditions, a number of such new compounds, and a process for their preparation.

Info

Publication number
IL120997A
IL120997A IL12099797A IL12099797A IL120997A IL 120997 A IL120997 A IL 120997A IL 12099797 A IL12099797 A IL 12099797A IL 12099797 A IL12099797 A IL 12099797A IL 120997 A IL120997 A IL 120997A
Authority
IL
Israel
Prior art keywords
formula
alkyl
phenyl
branched
compound
Prior art date
Application number
IL12099797A
Other languages
English (en)
Hebrew (he)
Other versions
IL120997A0 (en
Original Assignee
Hoechst Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19622737A external-priority patent/DE19622737A1/de
Priority claimed from DE1996129815 external-priority patent/DE19629815A1/de
Application filed by Hoechst Ag filed Critical Hoechst Ag
Publication of IL120997A0 publication Critical patent/IL120997A0/xx
Publication of IL120997A publication Critical patent/IL120997A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
IL12099797A 1996-06-07 1997-06-05 Pharmaceutical preparations containing a history of xanthine are converted into positions 1 and 3 for the treatment and prevention of shock conditions, a number of such new compounds, and a process for their preparation. IL120997A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19622737A DE19622737A1 (de) 1996-06-07 1996-06-07 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung
DE1996129815 DE19629815A1 (de) 1996-07-24 1996-07-24 Verwendung von Theophyllinderivaten zur Behandlung und Prophylaxe von Schockzuständen, neue Xanthinverbindungen und Verfahren zu deren Herstellung

Publications (2)

Publication Number Publication Date
IL120997A0 IL120997A0 (en) 1997-11-20
IL120997A true IL120997A (en) 2001-06-14

Family

ID=26026372

Family Applications (1)

Application Number Title Priority Date Filing Date
IL12099797A IL120997A (en) 1996-06-07 1997-06-05 Pharmaceutical preparations containing a history of xanthine are converted into positions 1 and 3 for the treatment and prevention of shock conditions, a number of such new compounds, and a process for their preparation.

Country Status (26)

Country Link
US (1) US6214992B1 (pt)
EP (1) EP0812844B1 (pt)
JP (1) JP4156687B2 (pt)
KR (1) KR100477177B1 (pt)
CN (1) CN1066146C (pt)
AR (1) AR007506A1 (pt)
AT (1) ATE226583T1 (pt)
AU (1) AU712277B2 (pt)
BR (1) BR9703499A (pt)
CA (1) CA2207120C (pt)
CZ (1) CZ292205B6 (pt)
DE (1) DE59708533D1 (pt)
DK (1) DK0812844T3 (pt)
ES (1) ES2185837T3 (pt)
HU (2) HU224958B1 (pt)
ID (1) ID19469A (pt)
IL (1) IL120997A (pt)
MX (1) MX9704203A (pt)
MY (1) MY117910A (pt)
NO (1) NO312400B1 (pt)
NZ (1) NZ328017A (pt)
PL (1) PL186576B1 (pt)
PT (1) PT812844E (pt)
RU (1) RU2201930C2 (pt)
SI (1) SI0812844T1 (pt)
TW (1) TW520285B (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9703044D0 (en) 1997-02-14 1997-04-02 Glaxo Group Ltd Phenyl xanthine esters and amides
GB9817623D0 (en) 1998-08-13 1998-10-07 Glaxo Group Ltd Pharmaceutical compounds
FR2804958B1 (fr) * 2000-02-15 2005-07-08 Hoechst Marion Roussel Inc Derives de xanthine, leur procede de preparation et les intermediaires de ce procede, leur application comme medicament et les compositions pharmaceutiques les renfermant
FR2804867B1 (fr) * 2000-02-15 2002-09-20 Hoechst Marion Roussel Inc Application de derives de xanthine pour la preparation d'un medicament destine a la prevention ou au traitement de l'osteoporose
UA80258C2 (en) * 2001-09-06 2007-09-10 Biogen Inc Methods of treating pulmonary disease
CN101538224A (zh) * 2002-05-31 2009-09-23 先灵公司 制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
SI1509525T1 (sl) * 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
CN112500413B (zh) * 2020-10-13 2024-03-01 安徽中医药大学 一类黄嘌呤芳酸醚衍生物，其制备方法及用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4735898A (en) 1985-07-16 1988-04-05 The University Of Virginia Alumini Patents Foundation Monoclonal antibodies and method of identifying species using the same
US4904472A (en) * 1987-04-10 1990-02-27 The University Of Virginia Alumni Patent Foundation Use of adenosine antagonists in the treatment of bradyarrhythmias and mechanical dysfunction associated with cardiopulmonary resuscitation
GB8826595D0 (en) * 1988-11-14 1988-12-21 Beecham Wuelfing Gmbh & Co Kg Active compounds
JPH03167186A (ja) * 1989-11-24 1991-07-19 Hokuriku Seiyaku Co Ltd キサンチン誘導体及びその用途
US5036683A (en) * 1990-06-04 1991-08-06 Geuvjehizian Moushegh Y Steering wheel lock protector
DE4019571A1 (de) 1990-06-20 1992-01-02 Hoechst Ag Pharmazeutische kombinationspraeparate enthaltend cephalosporin- und xanthinderivate und deren verwendung
DE19540798A1 (de) * 1995-11-02 1997-05-07 Hoechst Ag Alkylxanthinphosphonate und Alkylxanthinphosphinoxide und deren Verwendung als Arzneimittel

Also Published As

Publication number Publication date
CN1066146C (zh) 2001-05-23
CA2207120C (en) 2007-05-08
HUP9701016A3 (en) 2004-11-29
EP0812844A3 (de) 1998-04-08
BR9703499A (pt) 1998-10-06
MY117910A (en) 2004-08-30
TW520285B (en) 2003-02-11
HU0500865D0 (en) 2005-11-28
IL120997A0 (en) 1997-11-20
HU224958B1 (en) 2006-04-28
PL186576B1 (pl) 2004-01-30
SI0812844T1 (en) 2003-02-28
RU2201930C2 (ru) 2003-04-10
PT812844E (pt) 2003-03-31
AR007506A1 (es) 1999-11-10
CZ174397A3 (en) 1997-12-17
CA2207120A1 (en) 1997-12-07
JP4156687B2 (ja) 2008-09-24
DE59708533D1 (de) 2002-11-28
EP0812844B1 (de) 2002-10-23
CN1169993A (zh) 1998-01-14
NZ328017A (en) 2001-05-25
JPH1059969A (ja) 1998-03-03
KR980008230A (ko) 1998-04-30
HU225040B1 (en) 2006-05-29
MX9704203A (es) 1998-04-30
NO972582L (no) 1997-12-08
PL320413A1 (en) 1997-12-08
AU712277B2 (en) 1999-11-04
ATE226583T1 (de) 2002-11-15
CZ292205B6 (cs) 2003-08-13
DK0812844T3 (da) 2003-02-17
EP0812844A2 (de) 1997-12-17
NO972582D0 (no) 1997-06-06
HU9701016D0 (en) 1997-07-28
US6214992B1 (en) 2001-04-10
ES2185837T3 (es) 2003-05-01
NO312400B1 (no) 2002-05-06
KR100477177B1 (ko) 2005-09-30
ID19469A (id) 1998-07-16
HUP9701016A2 (hu) 1998-12-28
AU2469897A (en) 1997-12-11

Similar Documents

Publication Publication Date Title
JP2988711B2 (ja) 縮合プリン誘導体
JP2928386B2 (ja) うつ病治療剤
TW200300081A (en) Pde9 inhibitors for treating cardiovascular disorders
EP0357788B1 (en) Pyridazinone derivatives
EP0369744B1 (en) Xanthine derivatives, process for their preparation and pharmaceutical compositions
Okushima et al. A novel class of cardiotonics. Synthesis and pharmacological properties of [4-(substituted-amino) phenyl] pyridazinones and related derivatives
US6214992B1 (en) Use of theophylline derivatives for the treatment and prophylaxis of states of shock, novel xanthine compounds and processes for their preparation
JPS626555B2 (pt)
US5635511A (en) Treatment of heart rhythm disorders by administration of 3-phenylsulfonyl-3,7-diazabicyclo[3.3.1]nonane compounds.
MXPA97004203A (en) Use of theophylline derivatives for the treatment and prophylaxis of states of shock, new compounds of xanthina and procedure for its preparation
CA3169832A1 (en) Use of jak inhibitors in preparation of drugs for treatment of jak kinase related diseases
US4600710A (en) β-Adrenergic receptor agonist alkylaminoalkyl pyridinemethanol derivatives
US4181657A (en) 2-Aminooctahydroindolo[2,3-a]quinolizines useful in treating cardiovascular disorders
US5380714A (en) 2-furyl-triazalo [1,5-a]-[1,3,5]triazines and pyrazolo [2,3-a][1,3,5]triazines
JPH06321944A (ja) ピリドピリミジンジオン類、その製造方法および薬剤としてのその使用
BE897208A (fr) Composes de carbostyryle
JPS6341460A (ja) 新規なジヒドロピリジン誘導体
JPH03128375A (ja) イミダゾキノロン誘導体
JPS5857380A (ja) ９，１０−置換２−メシチルイミノ−３−アルキル−３，４，６，７−テトラヒドロ−２Ｈ−ピリミド（６．１−ａ）イソキノリン−４−オン
EP0272226A2 (en) 8-Azaxanthines alkylaminoalkyl or heterocyclylalkyl-substituted on the triazole ring, the salts thereof which are physiologically acceptable, their pharmaceutical compositions having antibronchospastic acivity, and the process for preparing the same
JPS63215672A (ja) ピリダジノン誘導体又はその塩類
NO143706B (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive 3-alkyl-7-(omega-1)-oksoalkylxantiner
JPH0276882A (ja) 光学活性ヒダントイン誘導体
CN115836050A (zh) 磺酰脲类衍生物及其医药用途
CA1296727C (en) 3-aminopropyloxyphenyl derivatives their preparation and pharmaceutical compositions containing them

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees